BeOne Medicines (ONC) Capital Expenditures Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (ONC) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 22,433.30% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -73.62% |
| 10 | Incyte | 25.57 Bn | 21.04 Bn | 1.57 Bn | -34.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.81% |
| Mar 31, 2026 | -27.93% |
| Dec 31, 2025 | -59.43% |
| Sep 30, 2025 | -64.02% |
| Jun 30, 2025 | -63.42% |
| Mar 31, 2025 | -61.67% |
| Dec 31, 2024 | -41.08% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | -9.48% |
| Mar 31, 2024 | 24.68% |
| Dec 31, 2023 | 29.34% |
| Sep 30, 2023 | 45.31% |
| Jun 30, 2023 | 271.64% |
| Mar 31, 2023 | 100.18% |
| Dec 31, 2022 | 5.55% |
| Sep 30, 2022 | 62.07% |
| Jun 30, 2022 | -15.17% |
| Mar 31, 2022 | 48.00% |
| Dec 31, 2021 | 231.46% |
| Sep 30, 2021 | 133.75% |